{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:38:13Z","timestamp":1792442293035,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ijantimicag.2016.11.021","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T05:17:08Z","timestamp":1486099028000},"page":"536-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Revival of old antibiotics: needs, the state of evidence and expectations"],"prefix":"10.1016","volume":"49","author":[{"given":"Hiba","family":"Zayyad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Eliakim-Raz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Leibovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mical","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0010","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cmi.2015.06.019","article-title":"Revival of old antibiotics: structuring the re-development process to optimize usage","volume":"21","author":"Theuretzbacher","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0015","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.cmi.2015.05.022","article-title":"Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin","volume":"21","author":"Giske","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0020","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21505594.2016.1207834","article-title":"Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae","author":"Thaden","year":"2016","journal-title":"Virulence"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.08.001","article-title":"Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case\u2013control\u2013control study","volume":"21","author":"Giacobbe","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0030","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/j.cmi.2015.06.005","article-title":"In vitro susceptibilities of clinical isolates of carbapenemase-producing Enterobacteriaceae to fosfomycin and tigecycline","volume":"21","author":"Choudhury","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0035","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.cmi.2015.06.007","article-title":"Use of old antibiotics now and in the future from a pharmacokinetic\/pharmacodynamic perspective","volume":"21","author":"Muller","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0040","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cmi.2015.05.002","article-title":"Optimization of dosing regimens and dosing in special populations","volume":"21","author":"Sime","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0045","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/jac\/dku064","article-title":"Product information for parenteral colistin varies substantially across Europe","volume":"69","author":"Theuretzbacher","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0050","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1128\/AAC.01361-08","article-title":"Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria","volume":"53","author":"Plachouras","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0055","doi-asserted-by":"publisher","first-page":"7324","DOI":"10.1128\/AAC.03508-14","article-title":"New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale","volume":"58","author":"Gregoire","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0060","author":"European Medicines Agency"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0065","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/cid\/ciw684","article-title":"The effectiveness and safety of high-dose colistin: prospective cohort study","volume":"63","author":"Benattar","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0070","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/cid\/ciw685","article-title":"Colistin dosing: does the fun ever start?","volume":"63","author":"Pogue","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0075","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","article-title":"Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"56","author":"Betrosian","year":"2008","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0080","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13063-015-0614-4","volume":"16","author":"Rosso-Fernandez","year":"2015","journal-title":"Trials"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0085","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0090","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0095","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1017\/S095026881200194X","article-title":"Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"141","author":"Aydemir","year":"2013","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0100","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0105","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jac\/dkw377","article-title":"Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis","volume":"72","author":"Zusman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0110","doi-asserted-by":"publisher","first-page":"e009956","DOI":"10.1136\/bmjopen-2015-009956","article-title":"Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol","volume":"6","author":"Dickstein","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0115","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0120","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0125","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/bmj.39421.435949.BE","article-title":"Chloramphenicol versus ampicillin plus gentamicin for community acquiredvery severe pneumonia among children aged 2\u201359 months in low resource settings: multicentre randomised controlled trial (SPEAR study)","volume":"336","author":"Asghar","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0130","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/jac\/dku530","article-title":"Efficacy and safety of chloramphenicol: joining the revival of old antibiotics? Systematic review and meta-analysis of randomized controlled trials","volume":"70","author":"Eliakim-Raz","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0135","doi-asserted-by":"publisher","first-page":"e007363","DOI":"10.1136\/bmjopen-2014-007363","article-title":"Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial","volume":"5","author":"Rosso-Fernandez","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0140","doi-asserted-by":"publisher","first-page":"e006723","DOI":"10.1136\/bmjopen-2014-006723","article-title":"Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial","volume":"5","author":"Shaw","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0145","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0150","doi-asserted-by":"publisher","first-page":"h6544","DOI":"10.1136\/bmj.h6544","article-title":"Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial","volume":"351","author":"Gagyor","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0155","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s10156-010-0079-z","article-title":"A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections","volume":"16","author":"Ceran","year":"2010","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0160","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.acuro.2012.06.007","article-title":"Randomized comparative study for the assessment of a new therapeutic schedule of fosfomycin trometamol in postmenopausal women with uncomplicated lower urinary tract infection","volume":"37","author":"Palou","year":"2013","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0165","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijgo.2011.03.014","article-title":"Comparison of single-dose and multiple-dose antibiotics for lower urinary tract infection in pregnancy","volume":"114","author":"Usta","year":"2011","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0170","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s10096-009-0805-6","article-title":"Fosfomycin in a single dose versus a 7-day course of amoxicillin\u2013clavulanate for the treatment of asymptomatic bacteriuria during pregnancy","volume":"28","author":"Estebanez","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0175","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/jac\/dkq237","article-title":"Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials","volume":"65","author":"Falagas","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0180","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0185","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0190","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0195","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0200","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/02813430601183074","article-title":"Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project","volume":"25","author":"Ferry","year":"2007","journal-title":"Scand J Prim Health Care"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0205","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/02813430802535312","article-title":"Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial","volume":"27","author":"Bjerrum","year":"2009","journal-title":"Scand J Prim Health Care"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0210","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s12879-014-0693-y","article-title":"Ibuprofen versus mecillinam for uncomplicated cystitis\u2014a randomized controlled trial study protocol","volume":"14","author":"Vik","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0215","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0220","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6\u2009g daily) in critically ill patients: continuous infusion versus three times daily administration","volume":"70","author":"Laterre","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0225","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1473-3099(15)00070-5","article-title":"Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial","volume":"15","author":"Kazemier","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0230","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/AOG.0b013e318195c2a2","article-title":"One-day compared with 7-day nitrofurantoin for asymptomatic bacteriuria in pregnancy: a randomized controlled trial","volume":"113","author":"Lumbiganon","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0235","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1001\/archinte.167.20.2207","article-title":"Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women","volume":"167","author":"Gupta","year":"2007","journal-title":"Arch Intern Med"},{"issue":"Suppl.","key":"10.1016\/j.ijantimicag.2016.11.021_bib0240","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.annemergmed.2012.06.104","article-title":"A pilot comparison of the efficacy of a 3-day course of nitrofurantoin versus 3-day ciprofloxacin in females with uncomplicated bacterial cystitis in the emergency department (conference abstract 127)","volume":"60","author":"Faine","year":"2012","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0245","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/jac\/dkv147","article-title":"Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials","volume":"70","author":"Huttner","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.ijantimicag.2016.11.021_bib0250","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007182.pub2","article-title":"Antimicrobial agents for treating uncomplicated urinary tract infection in women","author":"Zalmanovici Trestioreanu","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0255","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJMoa1507476","article-title":"Trimethoprim\u2013sulfamethoxazole versus placebo for uncomplicated skin abscess","volume":"374","author":"Talan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0260","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.annemergmed.2010.03.002","article-title":"Randomized controlled trial of trimethoprim\u2013sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection","volume":"56","author":"Schmitz","year":"2010","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0265","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jpeds.2015.10.044","article-title":"Trimethoprim\u2013sulfamethoxazole therapy reduces failure and recurrence in methicillin-resistant Staphylococcus aureus skin abscesses after surgical drainage","volume":"169","author":"Holmes","year":"2016","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0270","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/cid\/ciw177","article-title":"A randomized trial of clindamycin versus trimethoprim\u2013sulfamethoxazole for uncomplicated wound infection","volume":"62","author":"Talan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0275","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1056\/NEJMoa1403789","article-title":"Clindamycin versus trimethoprim\u2013sulfamethoxazole for uncomplicated skin infections","volume":"372","author":"Miller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0280","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1128\/AAC.00206-07","article-title":"Prospective randomized trial of empiric therapy with trimethoprim\u2013sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus","volume":"51","author":"Cenizal","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0285","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/S0140-6736(14)60841-2","article-title":"Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial","volume":"384","author":"Bowen","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0290","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/jac\/dku352","article-title":"Randomized non-inferiority trial to compare trimethoprim\/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection","volume":"70","author":"Harbarth","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0295","doi-asserted-by":"publisher","first-page":"h2219","DOI":"10.1136\/bmj.h2219","article-title":"Trimethoprim\u2013sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial","volume":"350","author":"Paul","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0300","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00467-008-0996-6","article-title":"Ceftibuten versus trimethoprim\u2013sulfamethoxazole for oral treatment of febrile urinary tract infection in children","volume":"24","author":"Marild","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0305","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/tropej\/fmn050","article-title":"Effectiveness of 3-day amoxycillin vs. 5-day co-trimoxazole in the treatment of non-severe pneumonia in children aged 2\u201359 months of age: a multi-centric open labeled trial","volume":"54","author":"Awasthi","year":"2008","journal-title":"J Trop Pediatr"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0310","author":"F\u00e4tkenheuer"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0315","first-page":"43","article-title":"Single-dose antibiotic treatment for symptomatic urinary tract infections in women: a meta-analysis of randomized trials","volume":"78","author":"Leibovici","year":"1991","journal-title":"Q J Med"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0320","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/jac\/dku379","article-title":"Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis","volume":"70","author":"Nemeth","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0325","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cmi.2015.05.012","article-title":"Improving predictions of the risk of resistance development against new and old antibiotics","volume":"21","author":"Andersson","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0330","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.08.003","article-title":"Nitrofurantoin's efficacy and safety as prophylaxis for urinary tract infections: a systematic review of the literature and meta-analysis of controlled trials","author":"Muller","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0335","author":"Friedland"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0340","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.10.023","article-title":"Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition","author":"Harris","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0345","article-title":"Closing the evidence gap in infectious disease: point-of-care randomization and informed consent","author":"Huttner","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0350","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.cmi.2015.07.004","article-title":"Strengths and limitations of industry vs. academic randomized controlled trials","volume":"21","author":"Laterre","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.11.021_bib0355","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/jac\/dkv157","article-title":"Reviving old antibiotics","volume":"70","author":"Theuretzbacher","year":"2015","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T10:28:14Z","timestamp":1658572094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917300237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0924857917300237"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.11.021","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revival of old antibiotics: needs, the state of evidence and expectations","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}